Calidi Biotherapeutics, Inc. (CLDI)
NYSE: CLDI · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Filings
324 filings since 2017 beside 82 insider forms · and emerging growth company · read from EDGAR on Nov 13, 2026Due next and emerging growth company
10-Q
Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by Nov 14, 2026
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 44 days after the quarter ended. The proxy statement was last filed Apr 29, 2026.
Filings a yearinsider forms included
2735961307741
2026 counts to Nov 13, 2026.
Listing warning from its exchange (8-K item 3.01): 2 times in the last 36 months, the newest Sep 25, 2026.Officer or director change (8-K item 5.02): 12 times in the last 36 months, the newest Jun 23, 2026.Auditor change (8-K item 4.01): 1 time in the last 36 months, the newest May 2, 2025.SEC letters: 25 in the last 36 months, the newest Aug 19, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Sep 25, 2026
8-K items 3.01, 8.01, 9.01
Listing warning from its exchange; Other event · Current report
Sep 21, 2026
Sep 22, 2026
8-K items 1.01, 8.01, 9.01
Major agreement signed; Other event · Current report
Sep 17, 2026
Aug 13, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Jul 31, 2026
8-K items 3.03, 5.03, 9.01
Change to shareholders' rights; Charter, bylaw or fiscal-year change · Current report
Jul 27, 2026
Jul 16, 2026
8-K items 1.01, 1.02, 2.03, 9.01
Major agreement signed; Major agreement ended; New debt or obligation taken on · Current report
Jul 10, 2026
Jun 23, 2026
8-K items 5.02, 7.01, 8.01, 9.01
Officer or director change; Investor disclosure (Regulation FD); Other event · Current report
Jun 17, 2026
May 29, 2026
8-K items 1.01, 3.02, 9.01
Major agreement signed; Shares sold without registration · Current report
May 28, 2026
May 14, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
May 8, 2026
8-K items 1.01, 3.02, 9.01
Major agreement signed; Shares sold without registration · Current report
May 6, 2026
Apr 2, 2026
8-K items 5.02, 8.01, 9.01
Officer or director change; Other event · Current report
Mar 29, 2026
Mar 27, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Mar 11, 2026
8-K items 1.01, 3.02, 8.01, 9.01
Major agreement signed; Shares sold without registration; Other event · Current report
Mar 5, 2026
Nov 13, 2025
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Nov 10, 2025
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Nov 7, 2025
Oct 31, 2025
8-K items 1.01, 1.02, 2.01, 9.01
Major agreement signed; Major agreement ended; Purchase or sale of a business completed · Current report
Oct 27, 2025
Oct 24, 2025
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Oct 22, 2025
Sep 19, 2025
8-K items 1.01, 5.02, 9.01
Major agreement signed; Officer or director change · Current report
Aug 8, 2025
40 of 324 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.